top of page
Pipeline AIM Biologicals AEZS-150 AEZS-130 (Macimorelin) Macimorelin Dx
Pipeline
Our Commercial and Development Pipeline is Focused on Serving the
Unmet Medical Needs of Patients Across a Range of Therapeutic Areas
Commercial Rights
Aeterna is regaining rights to macimorelin (Macrilen™) in the United States and Canada in May 2023 and is engaged in robust business development efforts to identify and secure a new development and commercialization partner in these territories.
bottom of page